Level Bio AB (publ) (NGM:LEVBIO)

Sweden flag Sweden · Delayed Price · Currency is SEK
0.446
+0.016 (3.72%)
At close: Mar 6, 2026
28.16%
Market Cap 30.51M
Revenue (ttm) 32.36M
Net Income (ttm) -3.54M
Shares Out 68.40M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 137,130
Average Volume 52,723
Open n/a
Previous Close 0.430
Day's Range n/a
52-Week Range 0.264 - 0.450
Beta 1.16
RSI 63.11
Earnings Date Feb 20, 2026

About Level Bio AB

Level Bio AB (publ) manufactures and distributes cutting-edge and diagnostic solutions in the Nordic region and internationally. It develops and manufactures diagnostic kits for the clinical market, as well as act as a distributor and full service partner to molecular biology labs in the Nordics. The company was formerly known as AlphaHelix Molecular Diagnostics AB (publ) and changed its name to Level Bio AB (publ) in May 2024. Level Bio AB (publ) was incorporated in 1998 and is headquartered in Stockholm, Sweden. [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 1998
Employees 10
Stock Exchange Nordic Growth Market
Ticker Symbol LEVBIO
Full Company Profile

Financial Performance

In 2025, Level Bio AB's revenue was 32.36 million, an increase of 28.94% compared to the previous year's 25.10 million. Losses were -3.54 million, -55.04% less than in 2024.

Financial Statements

News

There is no news available yet.